Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Context: Magrolimab is a monoclonal antibody blocking CD47, a “don't eat me” signal overexpressed on cancer cells, which leads to tumor phagocytosis and is synergistic with azacitidine. A high unmet need exists to build on current standard-of-care azacitidine in patients with HR MDS. Objective: Report final safety/tolerability and efficacy data. Design: Ph1b trial of magrolimab+azacitidine (NCT03248479). Patients: 95 patients with untreated HR MDS (intermediate, high, or very-high risk per the Revised International Prognostic Scoring System [IPSS-R]). Interventions: Magrolimab IV 1-mg/kg (priming) then 30-mg/kg ramp-up QW/Q2W (maintenance). Azacitidine 75 mg/m2 IV/SC days 1-7 (each 28-day cycle). Main Outcome Measures: Primary endpoints were safety/tolerability and complete remission (CR) rate. Results: Median age was 69y [range, 28-91y]). IPSS-R risk was intermediate, high, or very high in 27%, 52%, and 21% of patients, respectively. Therapy-related MDS, TP53 mutation, and poor-risk cytogenetics were reported in 22%, 26%, and 62% of patients, respectively. Median number of cycles was 6 (range, 1-27). The most common treatment-emergent adverse events (TEAEs) included constipation (68%), thrombocytopenia (55%), anemia (52%), neutropenia (47%), nausea (46%), and diarrhea (43%). The most common grade 3/4 TEAEs included anemia (47%), neutropenia (46%), thrombocytopenia (46%), and white blood cell count decreased (30%). Six patients discontinued treatment due to AEs. The 60-day mortality rate was 2%. Median hemoglobin change from baseline at first post dose sample was -0.7 g/dL (range, -3.1 to 2.4 g/dL). CR and objective response (OR) rates were 33% and 75%; 31% of OR-evaluable patients with baseline abnormal cytogenetics had cytogenetic CR. Median time to first OR, duration of CR, duration of OR, and progression-free survival were 1.9, 11.1, 9.8, and 11.6 months, respectively. 12- and 24-month overall survival (OS) rates were 75% and 52%, respectively; median OS was not reached with 17.1 months of follow-up. Favorable outcomes were observed in patients with TP53 mutation (n=25; CR rate, 40%; median OS, 16.3 months) and wild-type TP53 (n=61; CR rate, 31%; median OS, not reached). Conclusions: Magrolimab+azacitidine was well tolerated, with promising efficacy in patients with untreated HR MDS, including those with TP53-mutated and –wild-type disease. A Ph3 trial of magrolimab/placebo+azacitidine (ENHANCE; NCT04313881) is ongoing.

Original publication




Journal article


Clinical Lymphoma, Myeloma and Leukemia

Publication Date





S314 - S315